Solanaceous Alkaloids
- Name
- Solanaceous Alkaloids
- Accession Number
- DBCAT000442
- Description
Alkaloids, mainly tropanes, elaborated by plants of the family Solanaceae, including Atropa, Hyoscyamus, Mandragora, Nicotiana, Solanum, etc. Some act as cholinergic antagonists; most are very toxic; many are used medicinally.
- Drugs
Drug Drug Description Nicotine A stimulatory alkaloid found in tobacco products that is often used for the relief of nicotine withdrawal symptoms and as an aid to smoking cessation. Ipratropium An anticholinergic drug used in the control of symptoms related to bronchospasm in chronic obstructive pulmonary disease (COPD). Hyoscyamine An anticholinergic indicated to treat functional gastrointestinal disorders, biliary and renal colic, and acute rhinitis. Atropine A muscarinic antagonist used to treat poisoning by muscarinic agents, including organophosphates and other drugs. Scopolamine A belladonna alkaloid with anticholinergic effects indicated for the treatment of nausea and vomiting associated with motion sickness and postoperative nausea and vomiting (PONV). Rivanicline Investigated for use/treatment in ulcerative colitis. Capsaicin A topical analgesic agent used for the symptomatic relief of neuropathic pain associated with post-herpetic neuralgia, as well as other muscle and joint pain. Fentonium Fentonium is an atropine derivative. Zucapsaicin A topical analgesic used as an adjunct to relieve severe pain of osteoarthritis of the knee in selected adult patients. Nonivamide Nonivamide is used as a topical analgesic and is also used as a flavoring ingredient , , . Methylatropine Not Annotated Dihydrocapsiate Dihydrocapsiate is under investigation in clinical trial NCT00999297 (Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate). Butropium A medication indicated to treat pain caused by gastrointestinal inflammation and ulcers, or diseases of the gallbladder. Nazartinib Nazartinib is under investigation in clinical trial NCT03529084 (Phase III Study of Nazartinib (EGF816) Versus Erlotinib/gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations). - Drugs & Drug Targets